The National Human Genome Research Institute announces an interest in providing funds for Administrative Supplements related to stakeholder engagement in genomic medicine research. These funds are intended to support partnerships between genomics researchers and stakeholders such as professional societies, payers, public health and regulatory agencies, communities, patients, patient groups, or caregivers, to enhance the translation of genomics research into improved clinical care or public health.

Topics of Interest

Stakeholder engagement has been shown to strengthen research studies and enhance the translation of research results into clinical care and public health. Additionally, the meaningful involvement and feedback of stakeholders such as professional societies, payers, public health and regulatory agencies, communities, patients, patient groups, or caregivers helps to understand, address, and overcome disparities in health and healthcare as well as identify and eliminate the reasons that some interventions and therapies are not implemented broadly. Studies are encouraged that will solicit and be responsive to stakeholder input regarding study design, conduct, and outcomes, and that will collaborate with relevant stakeholders throughout the research process. Including stakeholders directly in the process of prioritizing, designing, and conducting research, and evaluating the partnership process is particularly encouraged.

Examples of research topics include, but are not limited to:

• Convening stakeholders through deliberative process or Town Hall approaches
• Adding stakeholders to project or consortium-wide Working Groups
• Including stakeholders in the development and dissemination of participant-centered approaches to informed consent and results disclosure in genomic studies
• Including stakeholders in the development and design of clinical genomic studies.

Eligibility

?This supplement opportunity is available to: (a)current NHGRI grantees who are part of existing research consortia that are not expected and/or supported to engage stakeholdersor (b)who are funded as independent investigators.

??

Description of circumstances for which administrative supplements are available.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• Application Due Date(s) May 15, 2020, by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include NOT-HG-20-031 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Requests are limited to 5 pages.
• Application budgets are limited to $100,000 total costs per year and must reflect the actual needs of the research experience. Institutions can request a maximum of one year of support.
• NHGRI anticipates making two awards contingent upon funds available and the submission of a sufficient number of meritorious applications
• The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.?
• To be eligible, the parent award must be active on July 31, 2021 and not be in an extension period.
• Applicants are strongly encouraged to consult with the Program Official of the parent grant or the contact listed below before submitting an application to confirm eligibility and to obtain technical assistance.
• Supplement requests under this Notice (and submitted to PA-18-591) will undergo administrative evaluation by NHGRI staff. Lower priority for funding will be given to grantees who belong to consortia that are already expected and/or supported to engage stakeholders.
• Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI administrative supplements.